Iron chelation therapy in MDS: Does it improve survival?

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 852-853

  Leitch, Heather A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Iron chelation therapy; Iron overload; Myelodysplastic syndrome

Indexed keywords

DEFEROXAMINE; IRON; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; EDITORIAL; ERYTHROCYTE TRANSFUSION; HIGH RISK PATIENT; HUMAN; IRON CHELATION; IRON OVERLOAD; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL TIME; THALASSEMIA; TREATMENT RESPONSE;

BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; OXIDATIVE STRESS; RISK; SURVIVAL ANALYSIS;

EID: 77952953505     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.005     Document Type: Editorial

References (13)

1. Gabutti V., Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996, 95(1):26-36.
2. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91(12):1588-1590.
3. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(30):7594-7603.
4. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?. Hematol Am Soc Hematol Educ Program 2009, 664-672.
5. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010, 34(7):864-870.
6. Leitch H.A., Leger C.S., Goodman T.A., Wong K.K., Wong D.H.C., Ramadan K.M., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2(3):205-211.
7. Fox F., Kundgen A., Nachtkamp K., Strupp C., Haas R., Germing U., et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 2009, 114(22):694a.
8. Ghoti H., Amer J., Winder A., Rachmilewitz E., Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007, 79(6):463-467.
9. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94(2):288-299.
10. Sanz G., Nomdedeu B., Such E., Bernal T., Belkaid M., Ardanaz T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112(11):238-239a.
11. List A.F., Baer M.R., Steensma D., Raza A., Esposito B., Virkus J., et al. Deferasirox (ICL670); exjade reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 2008, 112(11):523a.
12. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.
13. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114(26):5251-5255.